Ira Sohn
Since 1996, the world-renowned Sohn Investment Conference has been the premier investment forum, bringing together the world's savviest investors to share fresh insights and strategies in support of pediatric cancer research and treatment.
Wall Street's best and brightest investors participate in this unique, 'must attend' event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset allocators and private investors. Most speakers manage large proprietary investment portfolios that have outperformed the market for many years and do not share their insights in any public forum, but they volunteer their time to the Conference for the benefit of the Foundation. All contributions support the Foundation's mission to support pediatric research and care.
View Older Stories View More Recent Stories
-
GAN Appoints Business Development Executive Marcus Yoder as Senior Vice President of Sales
-
Britta Will, Ph.D., Wins Pershing Square Sohn Prize for Cancer Research
-
The Pershing Square Sohn Cancer Research Alliance Awards $4.2M to Seven Rising Leaders in Cancer Research
-
Halio Smart-Tinting Glass Earns Top Product of the Year Award from Environment + Energy Leader
-
Halio Smart-Tinting Glass Earns Top Product of the Year Award from Environment + Energy Leader
-
Recruiter.com to Present at Zooming with LD
-
GAN Provides June 2020 Internet Gambling Market Update for Pennsylvania as Reported by the Pennsylvania Gaming Control Board
-
131 Underserved Youth Nationwide Awarded Over $2.5 Million In Scholarships
-
GAN Provides June 2020 Internet Gambling Market Update for New Jersey as Reported by Division of Gaming Enforcement
-
2020 Extreme Tech Challenge (XTC) Global Finals Brings Together Highly Innovative Startups Tackling the World’s Biggest Challenges
-
Legal Industry Innovator Ed Sohn Joins Factor as Head of Solutions
-
Peacock Launches Nationally Tomorrow With Free And Premium Tiers
-
Recruiter.com CEO to Participate in Investor Webinar and Q&A Session on July 14
-
Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia
-
Recruiter.com Interview to Air on Bloomberg International on the RedChip Money Report
-
ATA Creativity Global Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
-
The Pershing Square Foundation Awards $3 Million to Innovative SARS-CoV-2 Research Projects
-
Recruiter.com Announces Results of its June 2020 Recruiter Index Survey as Seen on CNBC
-
Recruiter.com Closes Oversubscribed Convertible Debenture Bridge Financing
-
GAN Announces Addition to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes
-
Recruiter.com Appoints Evan Sohn as CEO
-
GAN Provides May 2020 Internet Gambling Market Update for Pennsylvania as Reported by the Pennsylvania Gaming Control Board
-
GAN Reports First Quarter 2020 Financial Results
-
U.S. economy starts long recovery as retail sales post record jump
-
GAN Provides May 2020 Internet Gambling Market Update for New Jersey as Reported by Division of Gaming Enforcement
-
Recruiter.com Index Presented Reasons for Job Market Optimism
-
Extreme Tech Challenge Announces Global Finalists, Debuts COVID-19 Innovation Award and Female Founder Award
-
GAN Schedules 2020 First Quarter Financial Results Conference Call for June 17, 2020
-
U.S. labor market unexpectedly improves; recovery years away
-
Form 4 LANDEC CORP \CA\ For: Jun 01 Filed by: Sohn Catherine A.
-
Form 4 LANDEC CORP \CA\ For: May 28 Filed by: Sohn Catherine A.
-
GAN Announces Cordish Gaming Group as a Major New Client of Internet Gambling in Pennsylvania
-
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Form 4 Rubius Therapeutics, For: May 21 Filed by: Sohn Catherine A.
-
Form 4 Axcella Health Inc. For: May 20 Filed by: Sohn Catherine A.
-
GAN Provides April 2020 Internet Gambling Market Update For Pennsylvania as Reported by the Pennsylvania Gaming Control Board
-
Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug
-
ATA Creativity Global Reports 2020 First Quarter Financial Results, Announces Adoption of Up to US$1 Million Share Repurchase Program
-
Enzychem Lifesciences Initiates Phase 2 Study for EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to Novel Coronavirus Pneumonia
-
GAN Reports April 2020 Internet Gambling Growth For New Jersey
-
M17 Entertainment Limited Announces US$26.5 Million in Series D funding
-
GAN Limited Announces Closing of IPO and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
GAN Limited to Ring the Nasdaq Stock Market Opening Bell in Celebration of its U.S. Initial Public Offering
-
ATA Creativity Global Schedules 2020 First Quarter Financial Results Release and Conference Call
-
Gainsco (GAN) Prices 6.38M Share Upsized IPO at $8.50/Sh
-
GAN Limited Announces Pricing of its Upsized U.S. Initial Public Offering
-
Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology
-
ATA Creativity Global Announces Filing of Annual Report on Form 20-F for the Year Ended December 31, 2019
-
UPDATE: GAN Limited (GAN) Announces Launch of 4.055M Share IPO Between $6.50-$8.50/Sh

